Nyxoah Sa's

The company develops the Genio system, a neurostimulation device for moderate to severe obstructive sleep apnea (OSA). Its competitors include emerging businesses developing neurostimulation therapies expected to launch in the United States in 2027, as well as invasive surgical treatments such as uvulopalatopharyngoplasty (UPPP) and maxillomandibular advancement (MMA), primarily for mild to moderate OSA. The company does not consider continuous positive airway pressure (CPAP) devices as direct competitors, as CPAP is typically the first-line therapy. Additionally, GLP-1 receptor agonists like Mounjaro (Tirzepatide) and Zepbound (Eli Lilly) have demonstrated positive effects on OSA in obese patients and are approved for treatment in the United States and Europe. Competitive factors include product safety, clinical data quality, reimbursement, procedure costs, ease of use, sales force effectiveness, manufacturing capabilities, innovation, and intellectual property. Competitors may have advantages such as greater financial resources, established distribution networks, faster regulatory approvals, and the ability to acquire complementary technologies or licenses. The company also competes with other medical technology firms for qualified personnel. Eli Lilly is identified as a competitor in company filings.